Daewoong "Diabetes Drug Enblo Aims for 100 Billion KRW Sales Within 3 Years"

Published 19 May.2023 16:02(KST)

Daewoong Pharmaceutical announced on the 19th that it aims to grow ‘Envlo’ (generic name: Inavogliflozin), the first domestically produced sodium-glucose co-transporter (SGLT)-2 inhibitor class diabetes drug launched on the 1st of this month, into a blockbuster with sales of 100 billion KRW within three years.

Daewoong Pharmaceutical's SGLT-2 inhibitor class diabetes treatment 'Envlo' <br>[Photo by Daewoong Pharmaceutical]

Daewoong Pharmaceutical's SGLT-2 inhibitor class diabetes treatment 'Envlo'
[Photo by Daewoong Pharmaceutical]

Envlo is the 36th domestic new drug and the first SGLT-2 inhibitor class diabetes treatment successfully localized by Daewoong Pharmaceutical among Korean pharmaceutical companies. It has been proven to have equal or greater blood sugar and glycated hemoglobin lowering effects and safety with only 0.3 mg, which is just 1/30th of the dose of other drugs in the same class, and it has also shown improvements in cardiovascular risk factors such as weight, blood pressure, and lipids.

Daewoong Pharmaceutical plans to actively promote Envlo’s strengths starting this month, the first month after its launch, to rapidly grow it into a blockbuster domestic new drug.

First, Daewoong Pharmaceutical is holding weekly symposiums to inform domestic medical professionals about Envlo’s unique advantages. They plan to continue these symposiums for two months across more than 20 cities nationwide. The first symposium, named ‘ENVLO-D’ to signify Envlo’s first step toward improving the quality of life for domestic and international diabetes patients, was held on the 3rd in Seoul and Daegu.

In addition, along with hosting symposiums, Daewoong Pharmaceutical is promoting Envlo’s excellent efficacy by participating in major endocrinology events such as international academic conferences and societies. At the recent Spring Academic Conference of the Korean Endocrine Society, Professor Lim Soo from Seoul National University College of Medicine introduced the role of the SGLT-2 inhibitor class and the latest clinical evidence of Envlo. Professor Lim stated, “Envlo’s ability to show comparable blood sugar lowering effects to drugs in the same class at a lower dose seems to be due to its strong binding to SGLT-2 and the relatively high urinary glucose excretion observed in clinical trials.”

Daewoong Pharmaceutical is applying its differentiated four-stage verified marketing strategy and sales operation system, built on accumulated sales power in the endocrinology field, to Envlo. Through Daewoong Pharmaceutical’s marketing know-how and sales capabilities, they plan to create synergy with Envlo’s product strength and lead to a successful market settlement.

Lee Chang-jae, CEO of Daewoong Pharmaceutical [Photo provided by Daewoong Pharmaceutical]

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “We will not only establish Envlo in the domestic market but also foster it as the best-in-class product in its category through active global expansion. We will make every effort to position it as the next blockbuster domestic new drug by entering 15 countries by 2025 and 50 countries by 2030.”